K 01-162 K162|cas:677746-25-7|西域试剂

K 01-162 K162,98.0%

产品编号：Bellancom-14533| CAS NO：677746-25-7| 分子式：C₁₅H₁₄BrN| 分子量：288.18

K 01-162 (K162) 结合到AβO (β-amyloid)将其破坏, EC50为80 nM。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14533	￥1600.00	杭州北京（现货）
Bellancom-14533	￥2550.00	杭州北京（现货）
Bellancom-14533	￥3950.00	杭州北京（现货）
Bellancom-14533	￥6300.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

K 01-162 K162

产品介绍

K 01-162 (K162) 抑制 Aβ 肽纤维的形成并消除其神经毒性。K 01-162 与 Aβ₄₂ 多肽结合，EC₅₀ 值为 80 nM。K 01-162 直接与 AβO 结合，KD 值为 19 μM。K 01-162 能够穿透大脑，可用于阿尔茨海默症的研究。

生物活性

K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ₄₂ peptide with an EC₅₀ value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease.

体外研究

K 01-162 (1 μM; 24 h) reduces the level of intracellular AβO.
K 01-162 (0.78-50 μM; 5 min) blocks the synaptic binding activity of AβO in mouse hippocampal neurons.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	MC65 cell line
Concentration:	1 μM
Incubation Time:	24 hours
Result:	Reduced the levels of SDS-stable Aβ trimer and larger aggregates.

体内研究
(In Vivo)

K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5xFAD mice with cerebral Aβ amyloidosis
Dosage:	100 μM
Administration:	Intracerebroventricular infusion; 100 μM 0.25 μL/h; for 2 weeks
Result:	Caused no apparent toxicity and significantly reduced the amyloid load in hippocampus to 50% of the mock-treated level.

体内研究

K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5xFAD mice with cerebral Aβ amyloidosis
Dosage:	100 μM
Administration:	Intracerebroventricular infusion; 100 μM 0.25 μL/h; for 2 weeks
Result:	Caused no apparent toxicity and significantly reduced the amyloid load in hippocampus to 50% of the mock-treated level.

体内研究

K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5xFAD mice with cerebral Aβ amyloidosis
Dosage:	100 μM
Administration:	Intracerebroventricular infusion; 100 μM 0.25 μL/h; for 2 weeks
Result:	Caused no apparent toxicity and significantly reduced the amyloid load in hippocampus to 50% of the mock-treated level.

性状

Solid

溶解性数据

In Vitro:

DMSO : 14.29 mg/mL (49.59 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4701 mL	17.3503 mL	34.7005 mL
5 mM	0.6940 mL	3.4701 mL	6.9401 mL
10 mM	0.3470 mL	1.7350 mL	3.4701 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1.43 mg/mL (4.96 mM); Suspended solution; Need ultrasonic

此方案可获得 1.43 mg/mL (4.96 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 14.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.43 mg/mL (4.96 mM); Clear solution

此方案可获得 ≥ 1.43 mg/mL (4.96 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 14.3 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.43 mg/mL (4.96 mM); Clear solution

此方案可获得 ≥ 1.43 mg/mL (4.96 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 14.3 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Li J, et al. Alzheimer's disease drug candidates stabilize A-β protein native structure by interacting with the hydrophobic core. Biophys J. 2011 Feb 16;100(4):1076-82. [Content Brief]

. Hong HS, et al. Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol Aging. 2010 Oct;31(10):1690-9. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

K 01-162 K162,98.0%

K 01-162 K162

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询